Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy.

Background: HER2-positive breast cancer occurs in 15-20% of breast cancer patients and is characterized by poor prognosis. Trastuzumab is considered the key drug for treatment of HER2-positive breast cancer patients. It improves patient survival; however, resistance to trastuzumab remains a challenge in HER2-positive breast cancer patients.

Preliminary results of targeted sequencing of and in a cohort of breast cancer families: New insight into pathogenic variants in patients and at‑risk relatives.

Breast cancer (BC) is the most commonly diagnosed cancer worldwide and a major health concern in Egypt. There is a known association between pathogenic variants identified in breast cancer susceptibility gene ()1 and 2 and the risk of developing BC. However, the number of studies investigating mutations in and in Egypt remains limited.